Name: Transparent Stock Valuation Data (English & German)
Creator: JVInvest
License: https://creativecommons.org/licenses/by/4.0/

Question 1

Is JVInvest stock valuation data free and transparent?

Accepted Answer

Yes, all valuation data on JVInvest is 100% free and transparent. We provide verifiable P/E ratios for the Top 100 global stocks, S&P 500, Nasdaq 100, and major indices worldwide. All data sources are disclosed so you can verify every calculation yourself.

Question 2

What valuation metrics are available on JVInvest?

Accepted Answer

JVInvest provides transparent P/E ratios for Top 100 global stocks (MSCI World), S&P 500, Nasdaq 100, DAX, FTSE 100, Nikkei 225 and more. All valuation metrics are verifiable with disclosed quarterly EPS data and market prices.

Question 3

Do I need to create an account to access the data?

Accepted Answer

No account or signup is required. All S&P 500 fundamental data is freely accessible without registration.

Question 4

How can I verify the P/E ratio calculations?

Accepted Answer

All our valuation data is 100% transparent. We disclose all data sources, quarterly EPS figures, and market prices used in calculations. You can verify every P/E ratio yourself using our transparent methodology.

Question 5

What is a Sankey chart for stocks?

Accepted Answer

A Sankey chart visualizes the flow of money through a company's financial statements - showing how revenue flows to costs, operating income, net income, and cash flows. JVInvest offers free Sankey charts for all S&P 500 companies.

Question 6

Which stock indices have free valuation data?

Accepted Answer

JVInvest provides free, verifiable valuation data for major global indices: S&P 500, Nasdaq 100, DAX 40, FTSE 100, CAC 40, Nikkei 225, and the Top 100 MSCI World stocks. All index P/E ratios are calculated transparently.

Question 7

What is the current S&P 500 P/E ratio?

Accepted Answer

JVInvest calculates and displays the current S&P 500 index P/E ratio based on the aggregate earnings of all constituent companies. Visit the Valuation page for the latest P/E ratio data.

Umsatz	65.18 USD bn
Bruttoergebnis	54.13 USD bn
Operatives Ergebnis	20.64 USD bn
Nettogewinn	20.64 USD bn
Nettomarge	31.7 %

Collaboration & Other Revenue	4.22 USD bn
Mounjaro	22.97 USD bn
Zepbound	13.48 USD bn
Trulicity	4.28 USD bn
Jardiance	3.43 USD bn
Other Cardiometabolic Health	4.01 USD bn
Verzenio	5.72 USD bn
Other Oncology	3.65 USD bn
Taltz	3.56 USD bn
Other Immunology	1.68 USD bn
Neuroscience	1.39 USD bn
Other Products	943 USD m

Eli Lilly and Company (LLY) Aktie: Umsatz, Gewinn, Margen & Bewertung

Eli Lilly and Company Kennzahlen (FY 2025)

Eli Lilly and Company Umsatz nach Segmenten

Geschäftsmodell von Eli Lilly and Company

Weitere Aktienanalysen wie Eli Lilly and Company